查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863428

心臟人工智慧监测和诊断市场（按产品类型、应用、最终用户、模式和人工智慧技术划分）—2025-2032年全球预测

Cardiac AI Monitoring & Diagnostics Market by Product Type, Application, End User, Modality, AI Technology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，心臟人工智慧监测和诊断市场将成长至 141.1 亿美元，复合年增长率为 29.85%。

主要市场统计数据
基准年 2024 17.4亿美元
预计年份：2025年 22.7亿美元
预测年份：2032年 141.1亿美元
复合年增长率 (%) 29.85%

对心臟人工智慧监测和诊断的发展趋势、临床驱动因素和关键营运挑战进行了简明扼要而又全面的概述。

在心臟健康领域，人工智慧正被快速且永续地融入监测和诊断工作流程，从而改变临床医生检测、分层和管理心血管疾病的方式。讯号处理、影像分析和预测演算法的进步使得更早检测心律不整、更精确地表征冠状动脉病变以及持续评估心臟衰竭生理状态成为可能。这些功能正逐步从专科医院扩展到门诊护理、家庭监测和消费级设备，从而催生新的临床管道和资料流，而这些都需要严格的检验、互通性和临床应用框架。

技术成熟度、感测器发展、监管政策明朗化以及经营模式创新如何共同重塑心臟人工智慧领域的应用管道和竞争格局

心臟人工智慧监测和诊断领域正经历多重相互关联的变革，这些变革加速了价值创造，同时也增加了规模化应用的难度。首先，演算法的复杂性已超越概念验证模型，发展成为能够整合心电图分析、影像学和纵向生理数据的临床相关系统。这种技术成熟度催生了模组化架构。透过将预测分析整合到诊断系统、监测平台和云端原生临床决策支援工具中，现在可以实现从急诊护理到家庭监测等各种临床场景的无缝部署。

评估 2025 年关税变化将如何影响整个心臟人工智慧生态系统（包括硬体和软体）的製造地、定价策略和采购行为。

2025年关税调整的累积影响将对供应链、采购决策以及心臟人工智慧监测和诊断设备的部署经济性产生连锁反应，尤其对于软硬体整合复杂的产品而言更是如此。影响进口硬体组件、成像系统和穿戴式装置组装的关税可能会推高单位成本，促使製造商重新评估其製造地、重新审视供应商关係并重新考虑定价策略。如果关税改变了设备的相对成本竞争力，医院和门诊机构的负责人可能会推迟资本投资，或转向利用现有感测基础设施的、更具成本效益的纯软体解决方案。

将产品架构、临床应用、终端用户环境、模式和人工智慧技术选择与采用可行性和临床价值连结起来的综合細項分析

細項分析揭示了产品架构、临床应用和最终用户环境如何交织，从而决定技术采纳和价值实现管道。就产品类型而言，诊断系统包括心电图分析系统和影像分析系统，前者专注于基于讯号的解读，后者专注于特定模态的影像处理工作流程。监测系统包括植入式、远端和穿戴式监测器，每种系统在资料收集连续性、侵入性和临床监测方面各有优劣。预测分析软体涵盖患者分层和风险预测，将纵向模型迭加到诊断或监测输入资料上，以产生可操作的临床警报并触发相应的诊疗路径。

美洲、欧洲、中东和非洲以及亚太地区在管理体制、采购重点和数位医疗成熟度方面的差异，将影响商业化策略和部署速度。

区域趋势将以不同的方式影响美洲、欧洲、中东和非洲以及亚太地区的监管预期、采购行为和扩张路径。在美洲，成熟的支付方环境和部分市场完善的监管管道正在推动人工智慧驱动的诊断和监测解决方案的早期应用，尤其是在那些致力于减少再入院率和管理慢性病的医疗系统中。该市场也倾向于重视临床证据的产生以及与电子健康记录系统的集成，以大规模展现其价值。

领先参与企业采取的策略性倡议结合了嵌入式硬体的卓越效能、云端原生分析以及伙伴关係主导的扩张，旨在加速临床应用并实现市场差异化。

心臟人工智慧监测和诊断领域的主要企业正在推行差异化策略，将卓越的硬体、演算法创新和生态系统协作相结合，以确保临床应用。一些现有企业正利用其成熟的影像医疗设备产品组合，将分析功能嵌入现有硬体平台，打造符合医院采购政策和企业IT需求的整合解决方案。这些公司强调临床检验、与电子病历的互通性以及长期服务合同，以此作为进入门槛。

为经营团队提供实用、多方面的指南，帮助他们整合临床检验、模组化产品设计、监管策略和基于结果的商业模式，从而实现规模化发展。

产业领导者应采取多管齐下的策略，将产品开发与临床通路、监管准备和灵活的商业模式结合。首先，应优先进行临床检验项目，在具有代表性的临床环境中产生真实世界证据，并重点关注具有临床意义的终点，例如减少不利事件、提高诊断准确性和降低资源消耗。这些研究应与医疗系统合作伙伴共同设计，以确保其与支付方的决策和报销申请相关。

采用方法严谨的混合方法调查方法框架，结合临床医师参与、技术基准化分析和情境分析，以检验策略结论。

我们的研究途径结合了严谨的一手研究和二手研究，以确保研究结果的可靠性和相关性。一手研究包括对临床医生、医疗系统管理人员、采购人员和技术开发人员进行结构化访谈，以了解实际工作流程、应用障碍和证据需求。此外，我们还组织专家圆桌会议和临床医生咨询小组，以检验临床路径，并根据实际决策场景对演算法输出进行压力测试。

策略重点的整合凸显了检验的效能、互通性和适应性商业化对于确定心臟人工智慧的长期影响和应用的重要性。

总之，心臟人工智慧监测和诊断技术正处于一个策略转折点，技术能力、不断变化的监管环境和医疗服务模式的转变在此交汇，既带来了巨大的机会，也带来了巨大的挑战。最具影响力的解决方案不仅要展现卓越的演算法效能，还必须融入临床医师的工作流程，符合健保报销原则，并透过模组化设计和适应性商业化策略来抵御供应链和关税波动的影响。鑑于区域监管和采购方面的差异，本地化的证据生成和基于试点项目的商业化对于建立信任和展现价值至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将深度学习演算法整合到远端心臟监测平台中，可将心律不整侦测率提高30%以上
  • 一家穿戴式科技製造商与一家人工智慧诊断公司合作，开发用于家庭监测的连续性心房颤动风险预测模型。
  • 透过实施多模态资料融合技术，整合心电图讯号、血流动力学参数和病患临床病史，实现个人化心臟人工智慧风险评估。
  • 透过获得监管部门核准并建立云端基础的、人工智慧驱动的心臟影像分析的报销管道，加速全球市场对该技术的接受度。
  • 引入可解释的AI框架用于心臟诊断，以增强临床医生的信心并满足不断变化的FDA透明度要求。
  • 即时人工智慧远距心臟诊断服务正在兴起，用于主动管理农村和资源匮乏地区的心臟衰竭患者。

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 心臟人工智慧监测和诊断市场（按产品类型划分）

  • 诊断系统
    • 心电图分析系统
    • 影像分析系统
  • 监控系统
    • 植入式监测器
    • 远端监控
    • 穿戴式监测器
  • 预测分析软体
    • 患者分层
    • 风险预测

第九章 心臟人工智慧监测和诊断市场（按应用领域划分）

  • 心律不整检测
    • 心房颤动
    • 室性心搏过速
  • 冠状动脉疾病诊断
    • 斑块特征
    • 狭窄检测
  • 心臟衰竭管理
    • 体液储存监测
    • 左心室射血分数（LVEF）评估
  • 高血压监测
    • 持续血压监测
    • 偶然血压筛检

第十章 按最终用户分類的心臟人工智慧监测和诊断市场

  • 门诊治疗中心
    • 诊断实验室
    • 门诊部
  • 诊所
  • 居家医疗环境
  • 医院

第十一章 心臟人工智慧监测与诊断市场（按模式划分）

  • CT分析
  • 心电图监测
    • 静态心电图
    • 动态心电图
  • 超音波心臟检查分析
    • 多普勒迴声
    • 二维迴声
  • 磁振造影分析

第十二章：人工智慧技术在心臟人工智慧监测与诊断市场的应用

  • 深度学习
    • 卷积类神经网路
    • 递迴神经网
  • 整合方法
    • 装袋
    • 提升
  • 机器学习
    • 逻辑迴归
    • 随机森林
    • 支援向量机

第十三章：心臟人工智慧监测与诊断市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：心臟人工智慧监测和诊断市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国心臟人工智慧监测与诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Koninklijke Philips NV
    • GE HealthCare Technologies, Inc.
    • Medtronic plc.
    • iRhythm Technologies, Inc.
    • AliveCor, Inc.
    • Apple Inc.
    • Samsung Electronics Co., Ltd.
    • HeartFlow, Inc.
    • Zebra Medical Vision Ltd.
    • Caption Health, Inc.
Product Code: MRR-5C6F41F5AF93

The Cardiac AI Monitoring & Diagnostics Market is projected to grow by USD 14.11 billion at a CAGR of 29.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.74 billion
Estimated Year [2025] USD 2.27 billion
Forecast Year [2032] USD 14.11 billion
CAGR (%) 29.85%

A concise yet comprehensive orientation to the emerging dynamics, clinical drivers, and operational imperatives shaping cardiac AI monitoring and diagnostic innovation

The cardiac healthcare landscape is undergoing a rapid and sustained integration of artificial intelligence into monitoring and diagnostic workflows, reshaping how clinicians detect, stratify, and manage cardiovascular disease. Advances in signal processing, imaging analytics, and predictive algorithms are enabling earlier identification of arrhythmias, more precise characterization of coronary pathology, and continuous assessment of heart failure physiology. These capabilities are progressively migrating from specialized hospital settings into ambulatory care, home monitoring, and consumer-facing devices, creating new clinical pathways and data flows that demand rigorous validation, interoperability, and clinical adoption frameworks.

Adoption is being driven by a convergence of technological maturity, regulatory clarity in key markets, and growing clinical evidence that AI-enabled tools can augment clinician decision-making without replacing essential clinical judgment. At the same time, healthcare systems face pressures to reduce readmissions, optimize diagnostic throughput, and extend specialist expertise into underserved settings. AI-driven cardiac monitoring and diagnostic platforms therefore represent both clinical enablers and operational levers for health systems seeking to deliver higher-value care.

This introduction sets the stage for a deeper analysis of the shifts altering competitive dynamics, how policy variables such as tariffs may influence supply chains, and what segmentation patterns reveal about clinical utility, buying behavior, and deployment environments. Readers should expect a synthesis that connects technical innovation with pragmatic commercialization and regulatory considerations to inform strategic decisions across clinical, product, and market development teams.

How technical maturation, sensor evolution, regulatory clarity, and commercial model innovation are jointly reshaping adoption pathways and competitive positioning in cardiac AI

The landscape of cardiac AI monitoring and diagnostics is being transformed by multiple intertwined shifts that accelerate value creation and complicate the path to scale. First, algorithmic sophistication has moved beyond proof-of-concept models to clinically relevant systems that integrate electrocardiogram analysis, imaging interpretation, and longitudinal physiologic data. This technical maturation is accompanied by modular architectures that allow predictive analytics to be embedded within diagnostic systems, monitoring platforms, and cloud-native clinical decision support tools, thereby enabling more seamless deployment across clinical settings from acute care to home monitoring.

Second, sensor miniaturization, improved battery life, and higher-fidelity signal acquisition have broadened the modalities through which cardiac data are captured. As a result, continuous ECG monitoring and wearable-derived metrics are progressively accepted in clinical pathways for arrhythmia detection and heart failure management. Third, regulatory frameworks are evolving to better accommodate AI-enabled medical devices, with a growing emphasis on post-market performance monitoring and real-world evidence generation. This regulatory evolution lowers some barriers to market entry while raising expectations for sustained clinical validation and transparency around model performance.

Fourth, commercial models are shifting from device-only transactions to outcome-oriented contracting and software-as-a-medical-device (SaMD) subscription models that tie reimbursement and procurement to measurable clinical or operational outcomes. Finally, interoperability and standards work are enabling richer data exchange between ambulatory devices, EHRs, and analytics platforms, accelerating integration into care pathways. Together, these transformative shifts demand that stakeholders design products and commercial strategies that are clinically credible, technically robust, and adaptable to evolving reimbursement and regulatory expectations.

Assessing how 2025 tariff shifts will influence manufacturing footprints, pricing strategies, and procurement behaviors across hardware-software cardiac AI ecosystems

The cumulative impact of tariff changes in 2025 will resonate across supply chains, procurement decisions, and the economics of deploying cardiac AI monitoring and diagnostic equipment, particularly for products with complex hardware-software integrations. Tariffs that affect imported hardware components, imaging systems, or wearable device assemblies increase unit costs and can prompt manufacturers to reassess manufacturing footprints, supplier relationships, and pricing strategies. Where tariffs alter the relative cost competitiveness of devices, buyers in hospitals and ambulatory settings may delay capital purchases or pivot to cost-effective software-only solutions that leverage existing sensing infrastructure.

Tariff-induced price pressures also incentivize firms to accelerate localization of manufacturing or to redesign products to rely more on software and cloud services that are less exposed to duties. However, localization entails near-term capital expenditure and regulatory recertification that can slow product rollouts. For vendors that rely on global supply networks for high-value imaging components or specialized sensors, tariffs can compress margins and push strategic shifts toward partnerships, contract manufacturing in lower-duty regions, or vertical integration to protect supply continuity.

On the payer and provider side, increased device costs may amplify interest in outcome-based procurement models where long-term cost offsets, such as reduced readmissions or avoided procedures, are highlighted to justify higher upfront expenditures. Conversely, smaller clinics and home care providers with tight budgets may postpone adoption of hardware-intensive solutions, increasing demand for remote monitoring services and predictive analytics that can be delivered via existing consumer-grade devices. Ultimately, the 2025 tariff environment will act as an accelerant for strategic choices around manufacturing footprint, product modularity, and commercial structures, and market participants should model tariff scenarios when evaluating capital allocation and partnership strategies.

Integrated segmentation analysis connecting product architectures, clinical applications, end-user environments, modalities, and AI technology choices to adoption potential and clinical value

Segmentation reveals how product architecture, clinical application, and end-user context intersect to determine pathways for technology adoption and value realization. When examining product types, diagnostic systems encompass electrocardiogram analysis systems and imaging analysis systems, with the former focused on signal-based interpretations and the latter on modality-specific image processing workflows. Monitoring systems span implantable monitors, remote monitors, and wearable monitors, each offering different trade-offs between continuity of data capture, invasiveness, and clinical oversight. Predictive analytics software covers patient stratification and risk prediction, layering longitudinal modeling on top of diagnostic or monitoring inputs to create actionable clinical alerts and care pathway triggers.

Applications emphasize specific clinical needs: arrhythmia detection, including atrial fibrillation and ventricular tachycardia subdomains, demands high sensitivity and low false-alarm rates to be clinically useful. Coronary artery disease diagnosis benefits from plaque characterization and stenosis detection capabilities that augment imaging interpretation and support interventional planning. Heart failure management leverages fluid retention monitoring and left ventricular ejection fraction assessment to guide therapy titration, while hypertension monitoring distinguishes between continuous blood pressure monitoring and occasional screening to support preventive care and chronic disease control.

End users range from ambulatory care centers, where diagnostic laboratories and outpatient clinics require rapid throughput and integration with referral workflows, to clinics, home care settings that prioritize ease of use and remote clinician oversight, and hospitals that require enterprise-grade interoperability and regulatory compliance. Modalities further differentiate solutions: CT analysis, ECG monitoring with resting and stress ECG contexts, echocardiogram analysis including Doppler and two-dimensional echo, and MRI analysis; each modality imposes distinct data preprocessing, annotation, and validation requirements. Finally, AI technology choices-deep learning architectures such as convolutional neural networks and recurrent neural networks, ensemble techniques including bagging and boosting, and classical machine learning methods like logistic regression, random forest, and support vector machines-drive both performance profiles and explainability trade-offs. Together, these segmentation lenses indicate that successful solutions will align algorithmic approach to clinical application, optimize modality-specific pipelines, and match delivery models to the practical constraints of target end users.

How divergent regulatory regimes, procurement priorities, and digital health maturities across Americas, Europe Middle East & Africa, and Asia-Pacific determine commercialization strategies and deployment pacing

Regional dynamics shape regulatory expectations, procurement behavior, and pathways to scale in distinct ways across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, a mature payer landscape and established regulatory pathways in some markets support early adoption of AI-enabled diagnostic and monitoring solutions, particularly where health systems are focused on readmission reduction and chronic disease management. This market often favors clinical evidence generation and integration with electronic health record systems to demonstrate value at scale.

The Europe Middle East & Africa region presents heterogeneous regulatory frameworks and reimbursement models that can both accelerate adoption in well-resourced markets and complicate entry elsewhere. Emphasis on data protection, interoperability standards, and national health technology assessment processes requires nuanced market entry strategies that account for localized clinical validation and stakeholder engagement. In the Asia-Pacific region, rapid digital health uptake, large patient volumes, and proactive public-private investment in health infrastructure create opportunities for scalable deployments, though local manufacturing policies and diverse regulatory regimes necessitate adaptive commercialization approaches. Across all regions, partnerships with health systems, strategic pilots to generate region-specific evidence, and tailored pricing models are pivotal to translating product capabilities into clinically adopted solutions.

Strategic approaches by leading players that combine embedded hardware prowess, cloud-native analytics, and partnership-driven expansion to accelerate clinical adoption and market differentiation

Key companies in the cardiac AI monitoring and diagnostics space are pursuing differentiated strategies that blend hardware excellence, algorithmic innovation, and ecosystem partnerships to secure clinical adoption. Some incumbents leverage established imaging and device portfolios to embed analytics into existing hardware platforms, creating integrated solutions that align with hospital procurement preferences and enterprise IT requirements. These firms emphasize clinical validation, interoperability with electronic records, and long-term service contracts as barriers to entry.

Innovative challengers focus on lean software architectures and cloud-native analytics that can be deployed rapidly across ambulatory and home-care settings. Their value propositions center on rapid iteration, consumer-grade user experiences, and scalable data ingestion from wearables and remote monitors. Partnerships between device manufacturers and analytics specialists are common, blending sensing expertise with advanced modeling capabilities to accelerate time to clinical utility. Additionally, a subset of companies is prioritizing explainability and regulatory readiness, investing in transparent model outputs, clinician workflow integration, and post-market performance monitoring to build trust with payers and providers.

Across the competitive set, strategic M&A and co-development agreements are used to fill capability gaps-whether that is advanced imaging analytics, embedded signal processing for implantable monitors, or business development in key regional markets. Firms that succeed will balance rigorous clinical evidence generation with pragmatic commercialization tactics that address procurement cycles, reimbursement realities, and interoperability demands.

Actionable, multi-faceted guidance for executive teams to align clinical validation, modular product design, regulatory strategy, and outcome-based commercial models for scale

Industry leaders should adopt a multi-dimensional strategy that aligns product development with clinical pathways, regulatory readiness, and flexible commercial models. First, prioritize clinical validation programs that generate real-world evidence across representative care settings, focusing on clinically meaningful endpoints such as reduction in adverse events, improved diagnostic yield, and reduced resource utilization. These studies should be designed collaboratively with health system partners to ensure relevance to payer decision-making and reimbursement dossiers.

Second, design modular product architectures that decouple sensor hardware from analytics software, enabling flexible deployment across implantable, remote, and wearable monitoring modalities while reducing exposure to tariff-driven hardware cost volatility. Third, invest in explainability and clinician-facing decision support that integrates seamlessly into existing workflows; embedding transparent model outputs and clear escalation pathways will accelerate clinician trust and adoption. Fourth, pursue regional go-to-market strategies that recognize differences in regulatory requirements and procurement processes, using targeted pilot programs to generate localized evidence and build payer momentum.

Finally, explore outcome-based contracting and subscription models that align vendor incentives with clinical and operational outcomes, and cultivate partnerships with device manufacturers, cloud providers, and health systems to create end-to-end solutions. By synchronizing evidence generation, product modularity, regulatory engagement, and commercial innovation, industry leaders can translate technical advances into sustained clinical and economic value.

A methodologically rigorous mixed-methods research framework combining clinician engagement, technical benchmarking, and scenario analysis to validate strategic conclusions

The research approach combines rigorous primary and secondary methods to ensure robustness and relevancy of findings. Primary research comprises structured interviews with clinicians, health system executives, procurement leads, and technology developers to capture real-world workflows, adoption barriers, and evidence requirements. These interviews are complemented by expert roundtables and clinician advisory panels to validate clinical pathways and to stress-test algorithm outputs against practical decision-making scenarios.

Secondary research synthesizes peer-reviewed literature, regulatory guidance documents, standards publications, and publicly available clinical trial registries to map the evidence landscape. Technical assessment of algorithmic approaches draws on open-source benchmarks and method comparisons to evaluate suitability for specific modalities and clinical applications. Data triangulation is achieved by cross-referencing primary insights with secondary sources and by applying scenario analysis to test the sensitivity of strategic implications to variables such as tariff changes, reimbursement shifts, and technology maturation.

Quality controls include independent peer review of clinical interpretations, reproducibility checks on technical claims, and validation of commercial intelligence through multiple stakeholder confirmations. Where proprietary datasets are used, methodology outlines provenance, preprocessing steps, and limitations to ensure transparent interpretation. This mixed-methods framework yields actionable insights while maintaining methodological rigor appropriate for executive decision-making and product strategy formulation.

Synthesis of strategic priorities showing why validated performance, interoperability, and adaptive commercialization will determine long-term impact and adoption in cardiac AI

In conclusion, cardiac AI monitoring and diagnostics occupy a strategic inflection point where technological capability, regulatory evolution, and changing care delivery models intersect to create substantial opportunity and complexity. The most impactful solutions will not only demonstrate superior algorithmic performance but will also embed into clinician workflows, align with reimbursement rationales, and be resilient to supply chain or tariff disruptions through modular design and adaptive commercialization strategies. Regional nuances in regulation and procurement necessitate localized evidence generation and pilot-based commercialization to build trust and demonstrate value.

Stakeholders should focus on generating clinically meaningful evidence, designing for interoperability and explainability, and engaging payers and providers early to align incentives. Companies that combine validated clinical performance with flexible deployment models and outcome-oriented commercial approaches will be best positioned to capture long-term adoption across hospitals, ambulatory centers, and home care settings. The strategic choices made now about validation, partnerships, and product architecture will determine which organizations transform technological advances into sustained improvements in cardiovascular care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of deep learning algorithms into remote cardiac monitoring platforms to improve arrhythmia detection rates by over thirty percent
  • 5.2. Collaboration between wearable technology manufacturers and AI diagnostics firms to develop continuous atrial fibrillation risk prediction models for home monitoring
  • 5.3. Implementation of multimodal data fusion combining ECG signals, hemodynamic parameters, and patient clinical history for personalized cardiac AI risk profiling
  • 5.4. Regulatory approvals and reimbursement pathways for cloud-based AI-driven cardiac imaging analysis accelerating global market adoption
  • 5.5. Adoption of explainable AI frameworks in cardiac diagnostics to enhance clinician trust and satisfy evolving FDA transparency requirements
  • 5.6. Emergence of real-time AI-enabled telecardiology services for proactive management of heart failure patients in rural and underserved regions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac AI Monitoring & Diagnostics Market, by Product Type

  • 8.1. Diagnostic Systems
    • 8.1.1. Electrocardiogram Analysis Systems
    • 8.1.2. Imaging Analysis Systems
  • 8.2. Monitoring Systems
    • 8.2.1. Implantable Monitors
    • 8.2.2. Remote Monitors
    • 8.2.3. Wearable Monitors
  • 8.3. Predictive Analytics Software
    • 8.3.1. Patient Stratification
    • 8.3.2. Risk Prediction

9. Cardiac AI Monitoring & Diagnostics Market, by Application

  • 9.1. Arrhythmia Detection
    • 9.1.1. Atrial Fibrillation
    • 9.1.2. Ventricular Tachycardia
  • 9.2. Coronary Artery Disease Diagnosis
    • 9.2.1. Plaque Characterization
    • 9.2.2. Stenosis Detection
  • 9.3. Heart Failure Management
    • 9.3.1. Fluid Retention Monitoring
    • 9.3.2. LVEF Assessment
  • 9.4. Hypertension Monitoring
    • 9.4.1. Continuous Blood Pressure Monitoring
    • 9.4.2. Occasional Blood Pressure Screening

10. Cardiac AI Monitoring & Diagnostics Market, by End User

  • 10.1. Ambulatory Care Centers
    • 10.1.1. Diagnostic Laboratories
    • 10.1.2. Outpatient Clinics
  • 10.2. Clinics
  • 10.3. Home Care Settings
  • 10.4. Hospitals

11. Cardiac AI Monitoring & Diagnostics Market, by Modality

  • 11.1. CT Analysis
  • 11.2. ECG Monitoring
    • 11.2.1. Resting ECG
    • 11.2.2. Stress ECG
  • 11.3. Echocardiogram Analysis
    • 11.3.1. Doppler Echo
    • 11.3.2. Two D Echo
  • 11.4. MRI Analysis

12. Cardiac AI Monitoring & Diagnostics Market, by AI Technology

  • 12.1. Deep Learning
    • 12.1.1. Convolutional Neural Network
    • 12.1.2. Recurrent Neural Network
  • 12.2. Ensemble Techniques
    • 12.2.1. Bagging
    • 12.2.2. Boosting
  • 12.3. Machine Learning
    • 12.3.1. Logistic Regression
    • 12.3.2. Random Forest
    • 12.3.3. Support Vector Machine

13. Cardiac AI Monitoring & Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cardiac AI Monitoring & Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cardiac AI Monitoring & Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Koninklijke Philips N.V.
    • 16.3.2. GE HealthCare Technologies, Inc.
    • 16.3.3. Medtronic plc.
    • 16.3.4. iRhythm Technologies, Inc.
    • 16.3.5. AliveCor, Inc.
    • 16.3.6. Apple Inc.
    • 16.3.7. Samsung Electronics Co., Ltd.
    • 16.3.8. HeartFlow, Inc.
    • 16.3.9. Zebra Medical Vision Ltd.
    • 16.3.10. Caption Health, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MODALITY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AI TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AI TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CARDIAC AI MONITORING & DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CARDIAC AI MONITORING & DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIAC AI MONITORING & DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ELECTROCARDIOGRAM ANALYSIS SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ELECTROCARDIOGRAM ANALYSIS SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ELECTROCARDIOGRAM ANALYSIS SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ELECTROCARDIOGRAM ANALYSIS SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ELECTROCARDIOGRAM ANALYSIS SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ELECTROCARDIOGRAM ANALYSIS SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMAGING ANALYSIS SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMAGING ANALYSIS SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMAGING ANALYSIS SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMAGING ANALYSIS SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMAGING ANALYSIS SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMAGING ANALYSIS SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MONITORING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMPLANTABLE MONITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMPLANTABLE MONITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMPLANTABLE MONITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMPLANTABLE MONITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMPLANTABLE MONITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY IMPLANTABLE MONITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REMOTE MONITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REMOTE MONITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REMOTE MONITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REMOTE MONITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REMOTE MONITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY REMOTE MONITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY WEARABLE MONITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY WEARABLE MONITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY WEARABLE MONITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY WEARABLE MONITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY WEARABLE MONITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY WEARABLE MONITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PREDICTIVE ANALYTICS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PATIENT STRATIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PATIENT STRATIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PATIENT STRATIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PATIENT STRATIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PATIENT STRATIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PATIENT STRATIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RISK PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RISK PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RISK PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RISK PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RISK PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RISK PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ARRHYTHMIA DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY VENTRICULAR TACHYCARDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY VENTRICULAR TACHYCARDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY VENTRICULAR TACHYCARDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY VENTRICULAR TACHYCARDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY VENTRICULAR TACHYCARDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY VENTRICULAR TACHYCARDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CORONARY ARTERY DISEASE DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PLAQUE CHARACTERIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PLAQUE CHARACTERIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PLAQUE CHARACTERIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PLAQUE CHARACTERIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PLAQUE CHARACTERIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY PLAQUE CHARACTERIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STENOSIS DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STENOSIS DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STENOSIS DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STENOSIS DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STENOSIS DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STENOSIS DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY FLUID RETENTION MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY FLUID RETENTION MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY FLUID RETENTION MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY FLUID RETENTION MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY FLUID RETENTION MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY FLUID RETENTION MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY LVEF ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY LVEF ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY LVEF ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY LVEF ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY LVEF ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY LVEF ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HYPERTENSION MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONTINUOUS BLOOD PRESSURE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONTINUOUS BLOOD PRESSURE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONTINUOUS BLOOD PRESSURE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONTINUOUS BLOOD PRESSURE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONTINUOUS BLOOD PRESSURE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONTINUOUS BLOOD PRESSURE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OCCASIONAL BLOOD PRESSURE SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OCCASIONAL BLOOD PRESSURE SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OCCASIONAL BLOOD PRESSURE SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OCCASIONAL BLOOD PRESSURE SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OCCASIONAL BLOOD PRESSURE SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OCCASIONAL BLOOD PRESSURE SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CT ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CT ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CT ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CT ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CT ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CT ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECG MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RESTING ECG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RESTING ECG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RESTING ECG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RESTING ECG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RESTING ECG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY RESTING ECG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STRESS ECG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STRESS ECG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STRESS ECG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STRESS ECG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STRESS ECG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY STRESS ECG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY ECHOCARDIOGRAM ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DOPPLER ECHO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DOPPLER ECHO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DOPPLER ECHO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DOPPLER ECHO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DOPPLER ECHO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DOPPLER ECHO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY TWO D ECHO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY TWO D ECHO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY TWO D ECHO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY TWO D ECHO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY TWO D ECHO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY TWO D ECHO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MRI ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MRI ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MRI ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MRI ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MRI ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY MRI ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AI TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY AI TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CARDIAC AI MONITORING & DIAGNOSTICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLO